Human height is a classic, highly heritable quantitative trait. To begin to identify genetic variants influencing height, we examined genome-wide association data from 4,921 individuals. Common variants in the HMGA2 oncogene, exemplified by rs1042725, were associated with height (P = 4 × 10−8). HMGA2 is also a strong biological candidate for height, as rare, severe mutations in this gene alter body size in mice and humans, so we tested rs1042725 in additional samples. We confirmed the association in 19,064 adults from four further studies (P = 3 × 10−11, overall P = 4 × 10−16, including the genome-wide association data). We also observed the association in children (P = 1 × 10−6, N = 6,827) and a tall/short case-control study (P = 4 × 10−6, N = 3,207). We estimate that rs1042725 explains ∼0.3% of population variation in height (∼0.4 cm increased adult height per C allele). There are few examples of common genetic variants reproducibly associated with human quantitativetraits; these results represent, to our knowledge, the first consistently replicated association with adult and childhood height.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
For the UK-based studies, collection of the type 2 diabetes cases was supported by Diabetes UK, BDA Research and the UK Medical Research Council (MRC) (Biomedical Collections Strategic Grant G0000649). The UK Type 2 Diabetes Genetics Consortium collection was supported by the Wellcome Trust (Biomedical Collections Grant GR072960). The ALSPAC study was supported by The UK MRC, the Wellcome Trust and the University of Bristol. The Exeter Family Study of Childhood Health was supported by UK National Health Service Research and Development and the Wellcome Trust. We also thank the Exeter University Foundation for funding. The UK GWA genotyping was supported by the Wellcome Trust (076113), and replication genotyping was supported by the Wellcome Trust, Diabetes UK, European Commission (EURODIA LSHG-CT-2004-518153) and the Peninsula Medical School. Personal funding comes from the Wellcome Trust (A.T.H.; Research Leave Fellow; Research Career Development Fellow); UK MRC (J.R.B.P.); Diabetes UK (R.M.F.) and the Throne-Holst Foundation (C.M.L.). M.N.W. is Vandervell Foundation Research Fellow at the Peninsula Medical School. C.M.L. is a University of Oxford Nuffield Department of Medicine Scientific Leader Fellow. C.N.A.P. and A.D.M. are supported by the Scottish executive as part of the Generation Scotland Initiative. We acknowledge the assistance of many colleagues involved in sample collection, phenotyping and DNA extraction in all the different studies. We thank K. Parnell, C. Kimber, A. Murray and K. Northstone for technical assistance. We thank S. Howell, M. Murphy and A. Wilson (Diabetes UK) for their long-term support for these studies. We also acknowledge the efforts of J. Collier, P. Robinson, S. Asquith and others at KBiosciences for their rapid and accurate large-scale genotyping. Finally, we acknowledge all participants in the various studies.
For the studies using the Scandinavian, US and Polish samples, the work was supported by a March of Dimes grant (#6-FY04-61) to J.N.H. and by a grant from The Center of Excellence in Complex Disease Genetics of the Academy of Finland (EU Projects GenomEUtwin, QLG2-CT-2002-01254) (L.P.). The FINRISK study was supported by the Sigrid Juselius Foundation. We thank members of our laboratories and of the Altshuler and Daly laboratories for helpful discussion, and we gratefully acknowledge all of the participants in the studies. We also thank J. Butler for excellent technical assistance and M. Kuokkanen for logistical help with the FINRISK97 cohort.
The whole-genome genotyping and analysis in the DGI genome scan (see Supplementary Note online for contributors) was supported by Novartis Institutes for BioMedical Research (to D. Altshuler), with additional support from The Richard and Susan Smith Family Foundation/American Diabetes Association Pinnacle Program Project Award (to D. Altshuler, J.N.H. and M.J. Daly). R.S. is supported by a US National Institutes of Health (NIH) Research Service Award. G.L. is supported by a March of Dimes research grant (6-FY04-61). Members of the DGI study group acknowledge support from an NIH/National Heart, Lung, and Blood Institute grant (U01 HG004171), the Burroughs Wellcome Fund and the Doris Duke Charitable Foundation. L.C.G. and members of the Botnia Study were funded by the Sigrid Juselius Foundation, the Finnish Diabetes Research Foundation, the Folkhalsan Research Foundation and Clinical Research Institute HUCH. The Malmö Study was funded by a Linné grant from the Swedish Research Council. L.C.G. is supported principally by the Sigrid Juselius Foundation, the Finnish Diabetes Research Foundation, The Folkhalsan Research Foundation and Clinical Research Institute HUCH. Work in Malmö, Sweden was also funded by a Linné grant from the Swedish Research Council. We thank the Botnia and Skara research teams for clinical contributions, and colleagues at Massachusetts General Hospital, Harvard, Broad and Novartis for discussions.
Supplementary Tables 1–6, Supplementary Methods, Supplementary Note